|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
1981
|
|
gptkbp:ATCCode
|
gptkb:A02BA02
|
|
gptkbp:bioavailability
|
50%
|
|
gptkbp:CASNumber
|
gptkb:66357-35-5
|
|
gptkbp:color
|
white to pale yellow crystalline powder
|
|
gptkbp:contraindication
|
hypersensitivity to ranitidine
|
|
gptkbp:drugClass
|
H2-receptor antagonist
antiulcer agent
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:halfLife
|
2.5-3 hours
|
|
gptkbp:hasInChIKey
|
XCVXDFGQTNKZRA-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C13H22N4O3S
|
|
gptkbp:hasSMILES
|
CN(C)C/C=C/C(=N/C#N)NCCSC(=O)N
|
|
gptkbp:hasUNII
|
884KT10YB7
|
|
gptkbp:hasWithdrawalReason
|
NDMA contamination
|
|
gptkbp:indication
|
gptkb:Zollinger-Ellison_syndrome
gptkb:gastroesophageal_reflux_disease
gptkb:peptic_ulcer
|
|
gptkbp:isApprovedDrug
|
false
|
|
gptkbp:isWithdrawnIn
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:legalStatus
|
expired
withdrawn
|
|
gptkbp:manufacturer
|
Glaxo (now GSK)
|
|
gptkbp:mechanismOfAction
|
gptkb:histamine_H2_receptor_antagonist
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
314.4
|
|
gptkbp:name
|
gptkb:Ranitidine
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1487
gptkb:DB00863
7797
6579
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
intravenous
|
|
gptkbp:sideEffect
|
diarrhea
constipation
dizziness
fatigue
headache
rash
|
|
gptkbp:synonym
|
gptkb:Zantac
gptkb:Azantac
gptkb:Ranitidin
gptkb:Ranitidina
|
|
gptkbp:target
|
HRH2 (Histamine H2 receptor)
|
|
gptkbp:bfsParent
|
gptkb:atorvastatin
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CHEMBL1487
|